Karyopharm Therapeutics Inc. (KPTI) stock
KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
$0.04−0.01 (-20.00%)
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
Karyopharm Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Karyopharm Therapeutics's total assets was $111.32M at Jun 30, 2026. For fiscal 2025 it was $108.42M, down 34.1% from the year before. Over ten years it grew -6.6% a year on average. The highest annual figure on record is $358.17M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.42M | -34.1% |
| FY2024 | Dec 31, 2024 | $164.42M | -31.6% |
| FY2023 | Dec 31, 2023 | $240.44M | -32.9% |
| FY2022 | Dec 31, 2022 | $358.17M | +17.3% |
| FY2021 | Dec 31, 2021 | $305.31M | -2.5% |
| FY2020 | Dec 31, 2020 | $313.05M | +6.1% |
| FY2019 | Dec 31, 2019 | $294.96M | -13.5% |
| FY2018 | Dec 31, 2018 | $341.19M | +89.2% |
| FY2017 | Dec 31, 2017 | $180.29M | -0.1% |
| FY2016 | Dec 31, 2016 | $180.39M | -16.3% |
| FY2015 | Dec 31, 2015 | $215.44M | -2.2% |
| FY2014 | Dec 31, 2014 | $220.34M | +39.3% |
| FY2013 | Dec 31, 2013 | $158.23M | +11969.1% |
| FY2012 | Dec 31, 2012 | $1.31M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $111.32M | +6.1% |
| Q1 FY2026 | Mar 31, 2026 | $131.42M | +2.9% |
| Q4 FY2025 | Dec 31, 2025 | $108.42M | -34.1% |
| Q3 FY2025 | Sep 30, 2025 | $96.23M | -49.2% |
| Q2 FY2025 | Jun 30, 2025 | $104.88M | -51.0% |
| Q1 FY2025 | Mar 31, 2025 | $127.71M | -37.5% |
| Q4 FY2024 | Dec 31, 2024 | $164.42M | -31.6% |
| Q3 FY2024 | Sep 30, 2024 | $189.48M | -29.8% |
| Q2 FY2024 | Jun 30, 2024 | $213.98M | -28.2% |
| Q1 FY2024 | Mar 31, 2024 | $204.46M | -37.2% |
| Q4 FY2023 | Dec 31, 2023 | $240.44M | -32.9% |
| Q3 FY2023 | Sep 30, 2023 | $269.96M | +16.7% |
| Q2 FY2023 | Jun 30, 2023 | $297.83M | +16.1% |
| Q1 FY2023 | Mar 31, 2023 | $325.80M | +10.8% |
| Q4 FY2022 | Dec 31, 2022 | $358.17M | +17.3% |
| Q3 FY2022 | Sep 30, 2022 | $231.24M | -9.0% |
| Q2 FY2022 | Jun 30, 2022 | $256.48M | -10.5% |
| Q1 FY2022 | Mar 31, 2022 | $294.03M | +7.0% |
| Q4 FY2021 | Dec 31, 2021 | $305.31M | -2.5% |
| Q3 FY2021 | Sep 30, 2021 | $254.09M | -24.7% |
| Q2 FY2021 | Jun 30, 2021 | $286.57M | -24.6% |
| Q1 FY2021 | Mar 31, 2021 | $274.91M | -33.9% |
| Q4 FY2020 | Dec 31, 2020 | $313.05M | +6.1% |
| Q3 FY2020 | Sep 30, 2020 | $337.59M | +13.4% |
| Q2 FY2020 | Jun 30, 2020 | $380.01M | +59.6% |
| Q1 FY2020 | Mar 31, 2020 | $416.14M | +44.9% |
| Q4 FY2019 | Dec 31, 2019 | $294.96M | -13.5% |
| Q3 FY2019 | Sep 30, 2019 | $297.75M | +35.3% |
| Q2 FY2019 | Jun 30, 2019 | $238.10M | -7.2% |
| Q1 FY2019 | Mar 31, 2019 | $287.21M | +96.2% |
| Q4 FY2018 | Dec 31, 2018 | $341.19M | +89.2% |
| Q3 FY2018 | Sep 30, 2018 | $219.99M | +34.3% |
| Q2 FY2018 | Jun 30, 2018 | $256.59M | +38.1% |
| Q1 FY2018 | Mar 31, 2018 | $146.37M | -5.8% |
| Q4 FY2017 | Dec 31, 2017 | $180.29M | -0.1% |
| Q3 FY2017 | Sep 30, 2017 | $163.77M | -10.8% |
| Q2 FY2017 | Jun 30, 2017 | $185.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $155.44M | – |
| Q4 FY2016 | Dec 31, 2016 | $180.39M | – |
| Q3 FY2016 | Sep 30, 2016 | $183.62M | – |
See a number that looks wrong?